Intracellular hypoxia measured by 18 F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

Aya Asano,Shigeto Ueda,Ichiei Kuji,Tomohiko Yamane,Hideki Takeuchi,Eiko Hirokawa,Ikuko Sugitani,Hiroko Shimada,Takahiro Hasebe,Akihiko Osaki,Toshiaki Saeki

Intracellular hypoxia measured by 18 F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

2018

Aya Asano
Shigeto Ueda
Ichiei Kuji
Tomohiko Yamane
Hideki Takeuchi
Eiko Hirokawa
Ikuko Sugitani
Hiroko Shimada
Takahiro Hasebe
Akihiko Osaki
Toshiaki Saeki

Background Hypoxia is a key driver of cancer progression. We evaluated the prognostic impact of 18F-fluoromisonidazole (FMISO) prior to treatment in patients with breast cancer.

Keywords:

Cancer research
Cancer
Breast cancer
FMISO
Hypoxia (medical)
Estrogen receptor
Positron emission tomography
18F-Fluoromisonidazole
Surgical oncology
Medicine
Oncology
Survival analysis
Progesterone receptor
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations